**Background and Aims** The availability of appropriate medicines for pediatric patients remains a challenge in any Health System. To evaluate the extent of this limitation in Portugal, the INFARMED, I.P., conducted the present study aiming at 1) knowing which extemporaneous formulations were prepared/used in hospital settings and 2) identifying which of these have a liquid formulation medicine available in Portugal, EU or USA.

**Methods** A cross sectional study was performed in nine Hospitals in Portugal regarding the collection of 2010 data on the use and production of extemporaneous formulations. The information was gathered through a questionnaire. Data analysis was restricted to medicines with more than 1000 formulations prepared or prescribed to more than 100 patients.

**Results** Thirty three medicines met the defined criteria. They were included in groups A and C of the ATC classification (Alimentary Tract and Metabolism and Cardiovascular System) with 8/35 (24.24%) each, followed by Anti-infectives for Systemic Use and Nervous System with 5/33 (15.15%) each. It was realized that 20 (75.76%) have a licensed oral liquid formulation either in Portugal, EU or USA. In Portugal 7 (21.21%) have or had a market authorization no longer available due to industrial ending. In addition, different hospitals prepare the same medicine in different formulations.

**Conclusions** The results confirmed the needs of Portugal in this area, identified potential lack of interest of the industry and recommend that strong action should be taken by the Regulatory Authority in the implementation of industrial manufacture authorization of small GMP batches of these medicines.

---

**Background and Aims** The use of ocular drugs in paediatrics is often “off-label”, concerning both safety in relation to the age and efficacy. For this reason we have deemed it necessary to examine prescribing habits of family paediatricians (pdf).

**Methods** Each pdf of Pordenone province (315,323 inhabitants) was sent a questionnaire where it was requested to list the ocular drugs usually prescribed, why they were prescribed and any side effect observed. They were also requested to confirm any use of dietary supplements or other medical devices.

**Results** All 35 pdf (34,440 children, aged 0–14 years) filled in the questionnaire. The most commonly prescribed drugs were antibiotics, anti-histamine agents and mast cell stabilizers for bacterial and allergic conjunctivitis. Only topical drugs were used. Children affected by serious ocular diseases were referred to ophthalmologists and of these only four assumed drugs for vernal keratoconjunctivitis and glaucoma (cyclosporine, timolol, dorzolamide and bimatoprost). Only minor adverse reactions (conjunctival hyperaemia, lid swelling) were found, even if potentially dangerous drug associations are still used (i.e. associations with steroids and/or sympathomimetic decongestants). No dietary supplements or medical devices were prescribed.

**Conclusions** Many ocular drugs lack reliable proof of efficacy and safety in paediatrics but fortunately their use outside the hospital seems limited. Nevertheless their use can probably be improved. Our research confirms the need to widen clinical studies of ocular drugs in paediatrics, not only concerning limited controlled trials but also their rational use.

---

**Background and Aims** Melatonin is not licensed for children in UK. Limited evidence is available about its efficacy and safety. We assessed parents’ satisfaction with melatonin for treatment of sleep problems in children.

**Methods** 27 children who were prescribed melatonin by community paediatricians at Bedford, UK were randomly selected. Structured questionnaire was given to their parents.

**Results**

1. Parents’ overall assessment of response to melatonin treatment - Good (63%), Average (33%), Poor (4%).
2. Analysis of age group of children with good response: 1–5 years (3 out of 5 children i.e. 100%), 6–10 years (7/12 i.e. 58%), 11–16 years (7/10 i.e. 70%), Over 16 years (0/2 i.e. 0%).
3. Effect on sleep when melatonin was stopped (in 18 children) - worsening (72%), same (28%), improvement (0%).
4. All the children had associated problems - 51% behavioural (autism, ADHD), 19% structural/chromosomal. 41% were in mainstream school, 55% special need school and 4% left school.
5. Improvement in behaviour secondary to improvement in sleep - yes (26%), No (74%).
6. Improvement in quality of life of parents secondary to fewer interruptions to their sleep - Yes (77%), No (23%).
7. Only 1 child had side effects including headache, confusion and tiredness while taking melatonin. He was on high dose of 10 mg/day.

**Conclusion** Most parents reported improvement in sleep of their children after being started on melatonin. Also majority reported better quality of life due to less interruption to their sleep.

---

**Background and Aims** Beta blockers are considered to be the most common prescribed class of drugs in treating cardiovascular diseases. However they are very useful in treating other conditions, such as migraine, glaucoma, hemangiomas, cirrhosis, etc.

We hypothesized that some beta blockers characteristics including their negative inotropic, peripheral vasoconstrictor and antiangiogenic effects might be potentially useful in the management of children with epistaxis.

To test this we sought to determine the efficacy of propranolol as a second line therapy in children with recurrent primary epistaxis, resistant to conventional management. From June 2010 to October 2011, a total of six children with this features were seen a our institution.

The overall effectiveness of propranolol for terminating epistaxis, given in dosage of 1.5–2 mg/kg/day, three times a day, was successful in all six treated children (100 % efficacy) becoming evident within 24 hours after the after the initiation of treatment. The epistaxis free interval period lasted at least one year, in five children and 43 days in one child.

Based on our first experiences with propranolol, we believe this drug could be promising treatment option for children with primary epistaxis.

---

**Background and Aims** The overall effectiveness of propranolol for terminating epistaxis, given in dosage of 1.5–2 mg/kg/day, three times a day, was successful in all six treated children (100 % efficacy) becoming evident within 24 hours after the after the initiation of treatment. The epistaxis free interval period lasted at least one year, in five children and 43 days in one child.

Based on our first experiences with propranolol, we believe this drug could be promising treatment option for children with primary epistaxis.